Journal Scans
Validation Study of a Quantitative Multigene Reverse Transcriptase–Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer
Recurrence Risk Assay Validated for Stage II Colon Cancer
RG Gray, P Quirke, K Handley, M Lopatin, L Magill, FL Baehner, C Beaumont, KM Clark-Langone, CN Yoshizawa, M Lee, D Watson, S Shak, DJ Kerr
Yes
20111007
2011 Nov 7
J Clin Oncol
Validation Study of a Quantitative Multigene Reverse Transcriptase–Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer
J Clin Oncol. 2011 Nov 7;[Epub Ahead of Print], RG Gray, P Quirke, K Handley, M Lopatin, L Magill, FL Baehner, C Beaumont, KM Clark-Langone, CN Yoshizawa, M Lee, D Watson, S Shak, DJ Kerr
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
SUMMARY
OncologySTAT Editorial Team
Adjuvant chemotherapy is of proven benefit in patients with stage III colon cancer; benefits in patients with stage II diseaseare more modest. Chemotherapy is usually restricted to patients with stage II disease with high-risk pathology. Additional markers are needed to assess risk of recurrence in stage II colon cancer and predict the benefit of adjuvant chemotherapy. Using strategies similar to those used to develop the Oncotype DX breast cancer assay, Gray et al developed a multigene reverse transcriptase–polymerase...
